Please login to the form below

Not currently logged in
Email:
Password:

Prism Ideas appoints Nigel Brooksby

Medical communications and drug development consultancy, Prism Ideas, has appointed Nigel Brooksby as non-executive chairman

Prism Ideas, a provider of medical communications and drug development consultancy services, has announced the appointment of Nigel Brooksby as non-executive chairman.

Brooksby has more than 35 years' experience in the life sciences industry, culminating in his position as chairman and managing director for sanofi-aventis UK and also successfully leading the UK's Association of the British Pharmaceutical Industry (ABPI) for two years.

Earlier this year Brooksby was made chairman of the board of trustees of the Primary Care Cardiovascular Society and was invited to join the advisory board of the Imperial Clinical Trials Unit at Imperial College London. In May, the Secretary of State for the Department for Business, Innovation and Skills (BIS) appointed him as a member of the Industrial Development Advisory Board.

"Prism Ideas is at a very exciting time in its development with a strong reputation for delivering scientific excellence and innovation," said Nigel Brooksby.

"I am delighted to be joining the company's leadership team and am looking forward to the opportunity to help build on its success."

1st September 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics